Monocyte chemoattractant protein-1: a&amp;nbsp;proinflammatory cytokine elevated in&amp;nbsp;sarcopenic obesity

Lim, Jun Pei; Leung, Bernard P.; Ding, Yew Yoong; Tay, Laura; Ismail, Noor Hafizah; Yeo, Audrey; Yew, Suzanne; Chong, Mei Sian

doi:10.2147/cia.s78901

Cited by 33 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a similar result has been shown in another cross-sectional study. The study has found the highest level of monocyte chemoattractant protein-1 (MCP-1) and the lowest level of appendicular lean mass in SO group (27), which supports the theory that low-grade inflammation is linked to SO.…”

Section: Low-grade Inflammationsupporting

confidence: 61%

Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments

et al. 2020

View full text Add to dashboard Cite

Sarcopenic obesity and diabetes are two increasing health problems worldwide, which both share many common risk factors, such as aging, and general obesity. The pathogenesis of sarcopenic obesity includes aging, physical inactivity, malnutrition, low-grade inflammation, insulin resistance, and hormonal changes. Nevertheless, there are two major reasons to cause diabetes: impaired insulin secretion and impaired insulin action. Furthermore, the individual diagnosis of obesity and sarcopenia should be combined to adequately define sarcopenic obesity. Also, the diagnosis of diabetes includes fasting plasma glucose test (FPG), 2-h oral glucose tolerance test (OGTT), glycated hemoglobin (A1C), and random plasma glucose coupled with symptoms. Healthy diet and physical activity are beneficial to both sarcopenic obesity and diabetes, but there are only recommended drugs for diabetes. This review consolidates and discusses the latest research in pathogenesis, diagnosis, and treatments of diabetes and sarcopenic obesity.

show abstract

Section: Low-grade Inflammationsupporting

confidence: 61%

Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Waters et al [ 63 ] found several functional deficits in the SO group relative to normal, sarcopenic and obese women, with the worst performance on the chair stands test by SO. However, Lim et al [ 55 ] found no significant difference across groups in this test, despite a longer observed time in the SO group [ 55 ].…”

Section: Discussionmentioning

confidence: 94%

“…Two additional studies support our results. First, Lim et al [ 55 ] found significant difference between these four sarcopenic-obesity groups in older Asian women from Singapore and concluded that obesity coupled with sarcopenia results in worsening of performance and strength parameters, including grip strength [ 55 ]. Second, Baumgartner et al [ 56 ] observed the lowest grip strength among sarcopenic obese men and women of 60 years and greater in a United States population, corroborating our results [ 56 ].…”

Section: Discussionmentioning

confidence: 99%

“…The observed lowest mean values of gait speed in women with SO, albeit non-significant, may reflect on their functional capacity and quality of life in the near future. While Meng et al [ 10 ] found an absence of association between gait speed and the groups (obesity, sarcopenia and SO) in older women [ 10 ], Lim et al [ 55 ] reported lower gait speed in sarcopenic obese older Asian men and women (≥65 years) from Singapore [ 55 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sarcopenic obesity and physical performance in middle aged women: a cross-sectional study in Northeast Brazil

et al. 2015

View full text Add to dashboard Cite

BackgroundSarcopenia and obesity have been independently associated with physical function decline, however little information is currently available on the relationship between sarcopenic obesity and physical performance, mainly in middle aged women. The present study aims to estimate the prevalence of sarcopenic obesity and to explore the relationship between sarcopenic obesity and physical performance in middle-aged women from Northeast Brazil.MethodsA cross-sectional study of women (40–65 years) living in Parnamirim, a city in Northeast Brazil (n = 491). Physical performance was assessed by grip strength, knee extensor and flexor strength (isometric dynamometry), gait speed, and chair stands. Using bioelectrical impedance analysis (BIA), appendicular skeletal muscle mass divided by height squared (kg / m2) was used to define sarcopenia. Waist circumference ≥ 88 cm was defined as abdominal obesity. Sarcopenic obesity was defined as the coexistence of obesity and sarcopenia. The physical performance outcomes were regressed in four groups defined by combinations of sarcopenia and obesity, adjusting for potential confounders (age, education and menopausal status).ResultsPrevalence rates of the four obesity-sarcopenia groups were: Sarcopenic obesity (7.1 %), obesity (67.4 %), sarcopenia (12.4 %) and normal (13 %). Women with sarcopenic obesity had significantly lower grip strength, weaker knee extension and flexion and longer time to raise from a chair compared with non-obese and non-sarcopenic women (p.values < 0.001). Except for the chair stands, these statistically significant differences were also found between sarcopenic obese and obese women. There was no significant difference for gait speed across the four groups (p = 0.50).ConclusionSarcopenic obesity was present in 7 % of this population of middle-aged women from Northeast Brazil and it was associated with poor physical performance. Sarcopenic obesity may occur in middle-aged women with performance limitations beyond pure sarcopenia-related muscle mass or obesity alone.

show abstract

“…The combined anti-inflammatory and pro-hypertrophy mechanism induced by conjugated OO jointly with exercise could be effective in preventing and treating T2D and associated complications. For example, reducing inflammatory cytokines could counteract muscle catabolism via actions on monocyte adhesion proteins such as monocyte chemoattractant protein-1 molecule (MCP1) [ 63 ].…”

Section: New Scope For Olive Oil Physical Activity and Lifestylementioning

confidence: 99%

Olive Oil Nutraceuticals in the Prevention and Management of Diabetes: From Molecules to Lifestyle

Alkhatib

Tsang

Tuomilehto

2018

IJMS

View full text Add to dashboard Cite

Lifestyle is the primary prevention of diabetes, especially type-2 diabetes (T2D). Nutritional intake of olive oil (OO), the key Mediterranean diet component has been associated with the prevention and management of many chronic diseases including T2D. Several OO bioactive compounds such as monounsaturated fatty acids, and key biophenols including hydroxytyrosol and oleuropein, have been associated with preventing inflammation and cytokine-induced oxidative damage, glucose lowering, reducing carbohydrate absorption, and increasing insulin sensitivity and related gene expression. However, research into the interaction of OO nutraceuticals with lifestyle components, especially physical activity, is lacking. Promising postprandial effects have been reported when OO or other similar monounsaturated fatty acids were the main dietary fat compared with other diets. Animal studies have shown a potential anabolic effect of oleuropein. Such effects could be further potentiated via exercise, especially strength training, which is an essential exercise prescription for individuals with T2D. There is also an evidence from in vitro, animal, and limited human studies for a dual preventative role of OO biophenols in diabetes and cancer, especially that they share similar risk factors. Putative antioxidative and anti-inflammatory mechanisms and associated gene expressions resulting from OO biophenols have produced paradoxical results, making suggested inferences from dual prevention T2D and cancer outcomes difficult. Well-designed human interventions and clinical trials are needed to decipher such a potential dual anticancer and antidiabetic effects of OO nutraceuticals. Exercise combined with OO consumption, individually or as part of a healthy diet is likely to induce reciprocal action for T2D prevention outcomes.

show abstract

Monocyte chemoattractant protein-1: a proinflammatory cytokine elevated in sarcopenic obesity

Cited by 33 publications

References 17 publications

Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments

Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments

Sarcopenic obesity and physical performance in middle aged women: a cross-sectional study in Northeast Brazil

Olive Oil Nutraceuticals in the Prevention and Management of Diabetes: From Molecules to Lifestyle

Contact Info

Product

Resources

About